Day One Biopharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Strong 2025 revenue growth was driven by OJEMDA’s launch, with new patient starts and therapy duration both increasing. Key pipeline updates are expected in 2025, including data from DAY301 and Emi-Le, while 2026 guidance targets 50% growth and further expansion into new indications.
-
Strong 2025 performance was driven by OJEMDA's rapid adoption and revenue growth, with expansion into frontline pLGG and global markets underway. The pipeline was strengthened by the Emmy Lee acquisition and DAY301 progress, with key data updates expected in 2026.
Fiscal Year 2025
-
Net product revenue grew 172% year-over-year to $155.4M in 2025, driven by OJEMDA's strong adoption in PLGG. The company ended the year with $441M in cash, no debt, and reiterated 2026 revenue guidance of $225M-$250M, while advancing pipeline programs and integrating Emi-Le.
-
The session highlighted strong commercial momentum for OJEMDA in pediatric glioma, supported by robust long-term data and high physician adoption. Pipeline progress includes the FIREFLY-2 trial, Day 301 ADC, and the Emi-Le program from the Mersana acquisition, all with key milestones expected by 2026.
-
The acquisition brings a first-in-class ADC for rare cancers, focusing on ACC with no approved targeted therapies. The $129M cash deal plus milestone payments leverages clinical expertise and aims for rapid regulatory progress, with potential to expand into other indications.
-
Q3 2025 delivered record revenue and double-digit growth for OJEMDA, driven by strong adoption, durable persistence, and positive long-term data. Full-year guidance was raised to $145–$150M, with a robust cash position and expanding market presence.
-
Q2 net product revenue grew 10% sequentially to $33.6M, with OJEMDA prescriptions up 15% and cumulative 12-month revenue at $113.1M. Full-year 2025 guidance is $140–$150M, driven by new patient starts and strong persistence.
-
OJEMDA’s launch has seen steady growth, driven by physician education and gradual adoption, especially in later therapy lines. Ongoing trials and new data presentations are building confidence, while international expansion and pipeline diversification remain strategic priorities.
-
OJEMDA's commercial launch exceeded expectations, with strong revenue and broad prescriber adoption. Clinical trials are progressing, with FIREFLY-2 enrollment on track and EU regulatory review underway. The pipeline is expanding with DAY301, and the company maintains a robust cash position for future growth.
-
Q1 2025 saw strong OJEMDA-driven revenue growth, with prescriptions up 16% and net product revenue reaching $30.5 million. Operating expenses declined sequentially, and the company ended the quarter with $473 million in cash and no debt, supporting ongoing pipeline and commercial expansion.
-
Strong initial OJEMDA launch drove $57M in eight months, with broad physician adoption and 10% market penetration in pLGG. Growth is expected to be steady, supported by new patient starts and long therapy duration, while pipeline asset DAY301 advances in early trials.
-
Ojemda's commercial launch drove strong 2024 revenue growth and high market penetration, supported by robust payer coverage and efficient sales execution. Pipeline progress includes the global Firefly II trial and DAY301 ADC, with a strong cash position enabling continued R&D and business development.
Fiscal Year 2024
-
Ojemda's 2024 launch drove $57.2M in net product revenue and exceeded expectations, with strong Q4 growth and broad payer coverage. The company ended the year with $531.7M in cash, advanced its pipeline, and expects steady growth in 2025.
-
Ojemda's launch for relapsed pLGG has seen strong physician uptake, high persistence, and consistent new patient starts, with efforts underway to expand use to earlier treatment lines. The competitive landscape remains favorable, and the DAY301 ADC program is set to begin clinical dosing soon.
-
Q3 2024 saw Ojemda net product revenue more than double sequentially, driven by strong demand, high payer approval, and expanding prescriber base. The company secured $73.7M in license revenue from Ipsen and ended the quarter with $558.4M in cash, supporting ongoing growth and pipeline expansion.